^
    17h
    Chronic Myelomonocytic Leukemia Revisited: A Comprehensive Review with Emphasis on the Oligomonocytic Subtype. (PubMed, Hum Pathol)
    Cases harboring biallelic TET2 inactivation or TET2+SRSF2 co-mutation show the highest bone marrow monocyte burden, frequent classical monocyte (MO1; CD14+/CD16-) elevation, and highest progression risk representing biologically true OM-CMML, whereas SF3B1-mutated and biallelic TP53 mutated cases show MDS-directed biology and warrant reclassification. This review synthesizes current diagnostic frameworks, molecular heterogeneity, risk stratification approaches, and evolving classification proposals, thereby providing a practical guide for pathologists navigating OM-CMML in the modern genomic era.
    Journal
    |
    TP53 (Tumor protein P53) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • CD14 (CD14 Molecule)
    |
    TP53 mutation • TET2 mutation • SF3B1 mutation • SRSF2 mutation
    1d
    EP0042-101: Study to Evaluate the Safety and Tolerability of EP0042 (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Ellipses Pharma | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Oct 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Venclexta (venetoclax) • azacitidine • EP0042
    2d
    CD69 blockade restores the bone marrow niche and delays leukemogenesis in a mouse model of Nras G12D-driven chronic myelomonocytic leukemia. (PubMed, Cancer Biol Ther)
    Anti-CD69 monoclonal antibody treatment was associated with reduced generation of granulocyte-macrophage progenitor cells, prolonged survival, and decreased Treg accumulation in the BME. Our findings suggest that CD69 may serve as a biomarker of BME immunological dysfunction in CMML.
    Preclinical • Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • CD69 (CD69 Molecule)
    |
    NRAS mutation • NRAS G12
    6d
    Cumulative incidence and prognostic factors for leukemic transformation in chronic myelomonocytic leukemia: a competing risk analysis. (PubMed, BMC Cancer)
    This study shows how competing-risk analysis complements standard Kaplan-Meier estimates of overall and progression-free survival when the cumulative incidence of a specific event, leukaemic transformation, is the quantity of interest. Although the modest, single-centre sample and non-randomised treatment allocation preclude definitive treatment recommendations, cytogenetic risk was the strongest disease-related prognostic factor, and molecular profiling provided additional risk discrimination within the NGS-tested subgroup. Cumulative incidence functions should therefore be reported routinely alongside Kaplan-Meier estimates in CMML and other myeloid neoplasms with non-negligible competing mortality.
    Journal
    |
    TP53 (Tumor protein P53) • SETBP1 (SET Binding Protein 1)
    8d
    Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Centre Hospitalier Universitaire de Nice | Unknown status --> Recruiting | Trial completion date: Nov 2018 --> Nov 2028 | Trial primary completion date: Nov 2018 --> Nov 2027
    Enrollment open • Trial completion date • Trial primary completion date
    8d
    A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm (clinicaltrials.gov)
    P2, N=0, Withdrawn, M.D. Anderson Cancer Center | Trial completion date: Aug 2029 --> Jun 2026 | Trial primary completion date: Aug 2027 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    azacitidine • Rezlidhia (olutasidenib)
    16d
    Comparative efficacy of donor lymphocyte infusions in augmenting graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies. (PubMed, Acta Haematol)
    DLI is an effective treatment strategy for post-transplant relapse of all myeloid malignancies, with specific genetic subtypes showing poorer outcomes and survival.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1)
    |
    TP53 mutation • KRAS mutation • NRAS mutation
    18d
    Chronic Myelomonocytic Leukemia (CMML) with Novel t(1;3)(p36.2;p12): Dual-locus Genomic Disruption Associated with Early Mortality. (PubMed, J Assoc Genet Technol)
    The 1p36.2 chromosomal region harbors tumor suppressors such as PR domain containing 16 (PRDM16), Tumor Protein 73 (TP73), Cadherin 5 or VE-cadherin (CHD5), and Kinase Family Member 1B (KIF1B), while the 3p12 chromosomal location plays a role in the malignant transformation and disruption of the tumor suppressors, focusing on the genomic instability observed in the case. These changes may partially harbor the capacity to contribute to the pathogenesis of aggressive behaviors in leukemia through failure of apoptosis, chromatin remodeling pathways, and enhanced self-renewal capabilities of stem cells.
    Journal
    |
    TP73 (Tumor Protein P73) • CDH5 (Cadherin 5) • KIF1B (Kinesin Family Member 1B) • PRDM16 (PR/SET Domain 16)
    18d
    Splicing factor mutations clearance and outcomes in clonal myeloid neoplasms: a referral center experience. (PubMed, Ann Hematol)
    Median OS was 27.2 vs. 17.2 months in AML and 16.7 vs. 23.7 months in MDS/CMML for clearance versus persistence groups, respectively. These findings suggest that SF mutation clearance does not significantly impact OS but may influence other clinical outcomes in patients with myeloid neoplasms harboring SF mutations.
    Journal
    |
    SF3B1 (Splicing Factor 3b Subunit 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    SF3B1 mutation • SRSF2 mutation
    18d
    Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations (clinicaltrials.gov)
    P2, N=25, Suspended, Abhay Singh, MD MPH | Recruiting --> Suspended
    Trial suspension • Tumor mutational burden
    |
    TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    TET2 mutation • Chr del(5q)
    |
    Promacta (eltrombopag)
    18d
    Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P1/2, N=34, Terminated, M.D. Anderson Cancer Center | Active, not recruiting --> Terminated; <75% participation
    Trial termination
    |
    Venclexta (venetoclax) • azacitidine
    19d
    Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P=N/A, N=31, Recruiting, Peking University People's Hospital | Phase classification: P4 --> P=N/A
    Phase classification
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    fludarabine IV • thiotepa • busulfan